U.S. Markets open in 5 hrs 43 mins

Natus Medical Inc (BABY) Files 10-K for the Fiscal Year Ended on December 31, 2017

- By insider

Natus Medical Inc (BABY) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Natus Medical Inc provides newborn care & neurology healthcare products & services used for screening, diagnosis, detection, treatment, monitoring & tracking of medical ailments in newborn care, epilepsy, sleep disorders, and balance & mobility disorders. Natus Medical Inc has a market cap of $968.900 million; its shares were traded at around $31.10 with and P/S ratio of 2.05. Natus Medical Inc had annual average EBITDA growth of 13.80% over the past ten years.

For the last quarter Natus Medical Inc reported a revenue of $131.4 million, compared with the revenue of $107.7 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $501.0 million, an increase of 31.2% from last year. For the last five years Natus Medical Inc had an average revenue growth rate of 9.1% a year.

The reported loss per diluted share was 62 cents for the year, compared with the earnings per share of $1.14 in the previous year. The Natus Medical Inc had an operating margin of 1.74%, compared with the operating margin of 14.47% a year before. The 10-year historical median operating margin of Natus Medical Inc is 9.64%. The profitability rank of the company is 6 (out of 10).

At the current stock price of $31.10, Natus Medical Inc is traded at 18.3% discount to its historical median P/S valuation band of $38.07. The P/S ratio of the stock is 2.05, while the historical median P/S ratio is 2.49. The stock lost 15.87% during the past 12 months.

For the complete 20-year historical financial data of BABY, click here.

This article first appeared on GuruFocus.